J Clin Oncol. 2010 Jun 7.
Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial.
Even the low incidence rate of cardiac disorder (5.1%) after long term herceptin treatment, it appears higher than control subjects. http://www.ncbi.nlm.nih.gov/pubmed/20530280
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment